Subject Index to Volume 48

N-Acetyl-aspartate levels
  lithium affecting, 740
ACTH. See also Corticotropin-releasing hormone
  plasma levels after naloxone, 310
  response to cold pressor test in Alzheimer’s disease, 247
Adaptive life functioning
  in schizophrenia, 163
Addiction
  gambling affecting heart rate and salivary cortisol, 948
  serotonin transporter gene polymorphisms in, 259
Adenylyl cyclase activity
  and signaling in bipolar disorder, 518
  calcium homeostasis affecting, 665
Adolescence
  depression in, orbitofrontal cytosolic choline levels in, 1053
  factors in onset of alcohol use, 265
Adrenal steroids
  and hippocampal neurogenesis, 801
  and hippocampal neuron loss in depression, 755
  and neurogenesis in adults, 715
  and neurotoxicity in HIV infection, 881
  and prefrontal cortex cell loss in depression, 766
  and structural plasticity of hippocampus, 721
α2A-Adrenoceptors
  binding sites affected by estrogen, 932
Affective disorders
  neural correlates of sadness and anxiety, 30
  and suicidal behavior related to serotonin transporter gene polymorphism, 259, 319
  and thyroid function in sleep deprivation, 323
Age
  and brain morphology in schizophrenia, 398
  and glial fibrillary acidic protein immunoreactivity in depression, 861
  and neuropsychologic function in schizophrenia, 137
Aged subjects
  hippocampal volume in geriatric depression, 301
  increased natural killer T cells in depression, 1024
  reduced orbitofrontal cortex volume in depression, 971
  synaptic proteins in schizophrenia, 184
AIDS-related dementia complex
  and neurotoxicity affected by steroid hormones, 881
Alcoholism
  association with bipolar and conduct disorders, 1037
  auditory P3a in male alcoholics, 276
  and course of bipolar disorder, 477
  factors in onset of adolescent alcohol use, 265
  and pediatric mania, 458
  serotonin transporter gene polymorphisms in, 259
Aldolase A
  brain levels affected by lithium, 58
Alzheimer disease
  cold pressor test in, 247
Amniotic fluid
  antidepressant concentrations in, 1032
cAMP
  response element–binding protein
    affecting cell survival, 732
    and expression of bcl-2 protein, 740
  signaling in bipolar disorder, 518
  calcium homeostasis affecting, 665
Amphetamine
  and striatal dopamine release affected by ketamine, 627
Amygdala
  MRI of men with bipolar disorder or schizophrenia, 147
  neuroimaging in depression, 813
  in pediatric anxiety, 51
  responses in schizophrenia, 81
Animal studies
  corticotropin-releasing hormone in stress, 1175
  early stress affecting brain structure and function, 778
  fear circuits in 5-HTA receptor knockout mice, 1157
  lithium regulation of aldolase A expression, 38
  object retrieval deficits from phencyclidine in monkeys, 415
  paroxetine binding to norepinephrine transporter in rats, 954-corr
  PET imaging of transgene expression, 337
  stress reactivity affected by maternal care, 1164
  valproate affecting endoplasmic reticulum stress proteins, 658
  ziprasidone affecting dopamine release in prefrontal cortex, 229
Anorexia nervosa
  CSF oxytocin and vasopressin levels in recovered subjects, 315
Antidepressants
  and adenyl cyclase activity, 518
  affecting serotonin receptors, 801
  augmentation by pindolol, 844
  in bipolar disorder, 558
  comparison of citalopram and sertraline, 894
  concentrations in amniotic fluid, 1032
  as maintenance therapy in bipolar disorder, 573
  selection in postgenomic era, 875-ed
Antiepileptic drugs
  in bipolar mania, 539

Abbreviations:
ed, editorial
corr, correspondence

© 2000 Society of Biological Psychiatry

0006-3223/00/$20.00
PII S0006-3223(00)01104-5
Antipsychotic drugs
and adaptive life functioning in schizophrenia, 163
in bipolar depression, 558
in bipolar mania, 539
as maintenance therapy in bipolar disorder, 573
and molecular mechanisms in schizophrenia, 173
ziprasidone affecting dopamine release in prefrontal cortex, 229

Anxiety
and altered fear circuits in knockout mice, 1158
genetics and brain function, implications for treatment of, 1142-ed
in childhood
amygdala in, 51
and pediatric mania, 458
in mood disorders, cerebral metabolism in, 1020
neural correlates of, 30
neurobiology of, 1145
and nightmares in posttraumatic stress disorder, 1081
and temperamental fearfulness, 1199

Apnea in sleep
and sleep architecture in depression, 1001

Apoptosis
and bcl-2 protein expression in schizophrenia, 641
in mood disorders, 732
mood stabilizers affecting, 740

Arousal systems
and gambling affecting heart rate and salivary cortisol, 948
in schizophrenia, 81

Associative learning in schizophrenia
and cerebellar function, 204
conditional, 406

Astroglia
age affecting glial fibrillary acidic protein immunoreactivity in depression, 861

Attention
time-of-day variations in, 1069

Attention-deficit/hyperactivity disorder
in adults, 9
familial association with conduct disorder, 21
and pediatric mania, 458
response inhibition in, 238
smooth pursuit eye movements in, 197

Auditory event-related potentials
lateralized P3 deficit in schizotypal personality disorder, 702
and onset of adolescent alcohol use, 265
P3a in male alcoholics, 276

Auditory-evoked fields
anomalous lateralization of M100 in psychosis, 1109

B lymphoblasts
calcium homeostasis affecting signaling in bipolar disorder, 665

Basal ganglia
activation in schizophrenia, 99
cocaine affecting, 685

Bcl-2 protein
expression in schizophrenia, 641
lithium affecting, 1
mood stabilizers affecting, 740

Behavioral therapy
and thalamic volume in pediatric obsessive–compulsive disorder, 294

Bilirubin
serum levels affected by skin light exposure, 1098

Bipolar disorder
antidepressants in, 558
antimanic agents in, 539
association with conduct disorder and substance use, 1037
calcium homeostasis and cAMP signaling in, 665
cingulate and caudate activity in mania, 1045
course affected by substance abuse, 477
development of acute phase treatments, 615
evaluation of clinical trials in psychiatry, 433-ed
family therapy in, 582
flexible treatment strategies, 605
interpersonal and social rhythm therapy, 593
lithium affecting N-acetyl-aspartate levels in brain, 1
lithium regulation of aldolase A expression, 58
maintenance treatment, 573
models of, 426-ed
MRI of temporal lobe structures in men, 147
natural history of, 445
neuroimaging in, 505
neuropathology of, 486
neuropsychologic findings in, 674
neurotrophic effects of mood stabilizers, 740
and pediatric mania, 458
perspectives of National Depressive and Manic-Depressive Association, 442
relation to schizophrenia, 531
research goals of NIMH, 436
and response to mecamylamine in Tourette’s syndrome, 1028
signal transduction in, 518
subtypes defined, 427-ed
treatment advances, 430-ed

Body dysmorphic disorder
family studies of, 287

Brain
N-acetyl-aspartate levels affected by lithium, 1
activated regions in schizophrenia, 99
aldolase A mRNA levels affected by lithium, 58
amygdala volumes in pediatric anxiety, 51
arousal systems in schizophrenia, 81
cerebellar function in schizophrenia, 204
frontal abnormalities in schizophrenia, 110
frontal lobe cytosolic choline levels in adolescent depression, 1053
functional connectivity alterations in schizophrenia, 1105
genetics and, 1142-ed
hippocampal volume in geriatric depression, 301
lateralization
auditory M100 in psychosis, 1109
auditory P3 deficit in schizotypal personality disorder, 702
magnetic resonance spectroscopy in schizophrenia, 357, 369
metabolism in anxiety with mood disorders, 1020
morphology assessment in schizophrenia, 1088
morphometrics in first-episode schizophrenia, 398
neural correlates of sadness and anxiety, 30
neuropathology in bipolar disorder, 486
regional blood flow
  affected by high and low frequencies in transcranial magnetic stimulation, 1133
cingulate and caudate activity in mania, 1045
  in guilt-related imagery, 43
structural plasticity
  and cell survival in mood disorders, 732
in depression, 713-ed
  in hippocampal remodeling, 721
structure and function after early stress, 778
synaptic proteins in schizophrenia, 184
thalamic volume in pediatric obsessive–compulsive disorder, 294
valproate affecting endoplasmic reticulum stress proteins, 658
Brain-derived neurotrophic factor
  affecting cell survival in mood disorders, 732
Bulimia nervosa
  CSF oxytocin and vasopressin levels in recovered subjects, 315
Bupropion
  in bipolar depression, 558
Buspirone
  in bipolar depression, 558
Calcium
  and glutamatergic neurotoxicity, 755
  homeostasis affecting cAMP signaling in bipolar disorder, 665
Calreticulin
  expression affected by valproate, 658
Cambridge Neuropsychological Test Automated Battery
  in mood disorders, 674
Cannabis abuse
  and course of bipolar disorder, 477
Carbamazepine
  and adenylyl cyclase activity, 518
  and aldolase A expression, 58
  as antimanic agent, 539
  in bipolar depression, 558
Carbon dioxide challenge test
  in relatives of panic disorder patients, 1223-corr
Caudate nucleus
  activity in bipolar mania, 1045
Cell adhesion molecules
  role in bipolar disorder, 486
Cerebellum
  function in schizophrenia, 204
neuropathology in bipolar disorder, 486
Cerebrospinal fluid
  oxytocin and vasopressin levels after recovery from eating disorders, 315
Child abuse
  affecting brain structure and function, 778
Children
  amygdala volumes in anxiety, 51
  brain imaging in obsessive–compulsive disorder, 1210
cortisol levels related to mother’s depression, 976
  familial attention-deficit disorder and conduct disorder comorbidity, 21
growth hormone levels in depression, 981
  pediatric mania, 458
  temperament related to anxiety, 1199
thalamic volume in obsessive–compulsive disorder, 294
Chlorpromazine
  as antimanic agent, 539
Choline
  orbitofrontal cytosolic levels in adolescent depression, 1053
Cholinergic system
  in hippocampus in schizophrenia, 381
Chromosome studies
  abnormalities in transsexualism, 1116
Cingulate gyrus, anterior
  activity in bipolar mania, 1045
  in guilt-related imagery, 43
  metabolic effects of fluoxetine in depression, 830
  neuroimaging in depression, 813
Circadian rhythms
  cortisol secretion in, 920
  interpersonal and social rhythm therapy in bipolar disorder, 593
  salivary cortisol levels in twins, 70
  salivary dehydroepiandrosterone levels in major depression, 989
  sleep and hormonal fluctuations in menstrual cycle, 1062
time-of-day variations in attention, 1069
Citalopram
  compared to sertraline, 894
Clinical trials
  antimanic agents, 539
  in bipolar depression treatment, 558
  design for flexible treatment strategies, 605
  evaluation of, 433-ed
  maintenance therapy in bipolar disorder, 573
  transcranial magnetic stimulation in depression, 962
Clomipramine
  affecting serotonin receptors, 801
  in bipolar depression, 558
Clorgyline
  in bipolar depression, 558
Clozapine
  as antimanic agent, 539
  as maintenance therapy in bipolar disorder, 573
  neutropenia from, granulocyte colony–stimulating factor levels in, 1113
Cocaine
basal ganglia changes from, 685
Cognition
deficits in mood disorders, 674
in schizophrenia
and emotion recognition, 127
and episodic object recognition, 651
and reactivity to stress, 1119
and symptom severity related to cortisol release, 1121
Cognitive behavioral therapy
and thalamic volume in pediatric obsessive–compulsive disorder, 294
Cold pressor test
in Alzheimer’s disease, 247
Comorbidity
anxiety in affective disorders, 1020
depression and physical illnesses, 791
posttraumatic stress disorder and depression, 878-ed, 902
response to mecamylamine in bipolar disorder with Tourette’s syndrome, 1028
Computer analysis
of sleep EEG, reliability of, 1010
Conditional associative learning
in schizophrenia, 406
Conduct disorder
association with bipolar disorder and substance use, 1037
familial association with attention-deficit disorder, 21
and pediatric mania, 458
Connectivity, functional
and touch feel illusion in schizophrenia, 1105
Corpus callosum
morphology in schizophrenia, 398
Cortical regions
disinhibition in male alcoholics, 276
neuropathology in bipolar disorder, 486
valproate affecting endoplasmic reticulum stress proteins, 658
Corticosteroids. See Adrenal steroids
Corticotropin-releasing hormone
and animal models of anxiety, 1175
brain levels affected by early stress, 778
and stress reactivity affected by maternal care, 1164
Cortisol
circadian rhythms in, 920
diurnal fluctuation in menstrual cycle, 1062
elevated levels related to symptom severity in schizophrenia, 1121
initial urine samples predicting posttraumatic stress disorder, 940
response to cold pressor test in Alzheimer’s disease, 247
salivary levels
in children, related to mother’s depression, 976
depression affecting, in twins, 70
gambling affecting, 948
Current Source Density
and auditory P3a in male alcoholics, 276
Dehydroepiandrosterone
and response to electroconvulsive therapy, 693
salivary levels in major depression, 989
Dendrites
stress-induced remodeling, 721
Dentate gyrus
adult neurogenesis in, 715, 721
Dependence
serotonin transporter gene polymorphisms in, 259
Depression. See also Bipolar disorder
in aged subjects
hippocampal volume in, 301
increased natural killer T cells in, 1024
reduced orbitofrontal cortex volume, 971
anxiety with, 30
cerebral metabolism in, 1020
and CSF oxytocin and vasopressin levels in eating disorders, 315
electroconvulsive therapy
in bipolar disorder, 558
response affected by DHEAS levels, 693
and fear circuits in 5-HT1A receptor knockout mice, 1157
and growth hormone levels in children, 981
hippocampal atrophy in, 721
and imidazoline binding sites affected by estrogen, 932
maternal, and cortisol levels in children, 976
neuroimaging studies, 813
neuronal activity and cell survival in, 732
and orbitofrontal cytosolic choline levels in adolescence, 1053
prefrontal cortex cell loss in, 766
in pregnancy, and fluoxetine affecting birth outcomes, 996
and responses to early stress, 778
serotonergic system imaging in, 801
sleep architecture and obstructive sleep apnea in, 1001
structural plasticity in, 713-ed
transcranial magnetic stimulation in, 959-ed, 962
high and low frequencies affecting brain activity, 1133
Depressive disorder, major
age affecting glial fibrillary acidic protein immunoreactivity in, 861
in aged subjects
increased natural killer T cells in, 1024
and reduced orbitofrontal cortex volume, 971
comorbidity
with physical illness, 791
with posttraumatic stress disorder, 878-ed, 902
hippocampal imidazoline receptor proteins in, 910
magnetic resonance imaging of brain changes, 791
mirtazapine affecting sleep in, 75
and neuron death in hippocampus, 755
neuropsychologic findings in, 674
plasma thymopoietin levels in, 65
regional metabolic effects of fluoxetine in, 830
relapse in tryptophan depletion, 327
response to ECT affected by DHEAS levels, 693
and salivary cortisol in twins, 70
salivary dehydroepiandrosterone in, 989
and thyroid function in sleep deprivation, 323
Deprivation
and neurogenesis in adults, 715
Desipramine
affecting serotonin receptors, 801
in bipolar depression, 558
Deterioration
and executive functions in schizophrenia, 137
Developmental psychopathology
attention-deficit/hyperactivity disorder in adults, 9
Diagnostic validity
attention-deficit/hyperactivity disorder in adults, 9
Divalproex
in bipolar depression, 558
Dopamine
amphetamine-induced release affected by ketamine, 627
brain levels in bipolar disorder, 486
D2 receptor reporter gene expression, 337
phencyclidine affecting, and impulsivity in monkeys, 415
release in prefrontal cortex affected by ziprasidone, 229
Dose–response curve
and ACTH levels after naloxone, 310
Dreams
and nightmares in posttraumatic stress disorder, 1081
Drug abuse
association with bipolar and conduct disorders, 1037
basal ganglia changes from cocaine, 685
course of bipolar disorder in cannabis abuse, 477
and impulsivity affected by phencyclidine in monkeys, 415
and pediatric mania, 458
Eating disorders
CSF oxytocin and vasopressin levels in recovered subjects, 315
family studies of, 287
Electroconvulsive therapy
in bipolar depression, 558
efficacy affected by stimulus intensity, 222
responses affected by plasma DHEAS levels, 693
Electroencephalography
power abnormalities in schizophrenia, 1088
in sleep, reliability of computer analysis in, 1010
Emotion
recognition deficit in schizophrenia, 127
Endoplasmic reticulum
stress proteins affected by valproate, 658
Environment
interactions with genetic factors, 1175
and neurogenesis in adults, 715
and responses to antidepressants, 875-ed
and stress reactivity affected by maternal care, 1164
Epigenetics
and parent-of-origin effect in schizophrenia, 706
Epinephrine
response to cold pressor test in Alzheimer’s disease, 247
Erratum
Thase article (1997;41:964–973), 171
Esthesioneuroblastoma, olfactory
and vasopressin levels in depression, 330
Estradiol
affecting serotonin receptor binding, 854
Estrogen
affecting imidazoline and α2A-adrenoceptor binding sites, 932
and neurotoxicity in HIV infection, 881
Event-related potentials
auditory
lateralized P3 deficit in schizotypal personality disorder, 702
and onset of adolescent alcohol use, 265
P3a in male alcoholics, 276
visual
and onset of adolescent alcohol use, 265
and response inhibition in attention-deficit disorder, 238
and response inhibition in schizophrenia or psychopathy, 210
Excitotoxins
and hippocampal neuron loss, 755
Executive functions
age affecting, in schizophrenia, 137
Expressed emotion
in family therapy of bipolar disorder, 582
Eye movements
assessment in schizophrenia, 1088
smooth pursuit in attentional dysfunction, 197
Eyelink conditioning
and cerebellar function in schizophrenia, 204
Families
attention-deficit disorder and conduct disorder in girls, 21
carbon dioxide challenge test in relatives of panic disorder patients, 1223-corr
cortisol levels in children related to mother’s depression, 976
factors in adolescent alcohol use, 265
maternal care in infancy affecting stress reactivity, 1164
neuropsychologic deficits in relatives of schizophrenic patients, 120
obsessive–compulsive disorder and other spectrum conditions, 287
parent-of-origin effect in schizophrenia, 706
risk analysis of association between three disorders, 1037
susceptibility to schizophrenia and bipolar disorder, 531
Family therapy
in bipolar disorder, 582
Fear
altered circuits in knockout mice, 1157
neurobiology of, 1144
and temperament linked to anxiety, 1199
First episodes
and brain morphometrics in schizophrenia, 398
and 6-month outcome measures, 467
Fluoxetine
in bipolar depression, 558
in pregnancy, affecting birth outcomes, 996
regional metabolic effects in depression, 830
Frontal lobe
  aldolase A expression affected by lithium, 58
  cytosolic choline levels in adolescent depression, 1053
  dysfunction in male alcoholics, 276
  structural abnormalities in schizophrenia, 110

G proteins
  activity in bipolar disorder, 486
  and calcium homeostasis, 665
  and signal transduction, 518

GABA<sub>Α</sub> receptor
  and response to ECT affected by plasma DHEAS levels, 693
  and stress reactivity affected by maternal care, 1164

Gabapentin
  as antimanic agent, 539
  in bipolar depression, 558

Gambling
  heart rate and salivary cortisol in, 948

Gender
  attention-deficit disorder and conduct disorder in girls, 21
  auditory P3a in male alcoholics, 276
  and brain morphology in schizophrenia, 398
  and emotion recognition in schizophrenia, 127
  MRI in bipolar disorder or schizophrenia in men, 147

Gender identity disorder
  and sex chromosome abnormality in transsexualism, 1116

Gene expression
  aldolase A mRNA levels affected by lithium, 58
  and mRNAs encoding synaptic proteins in schizophrenia, 184

Genetic factors
  and brain function, 1142-ed
  in childhood anxiety, 1199
  in familial attention-deficit disorder and conduct disorder, 21
  interactions with environmental factors, 1175
  linkage of bipolar disorder and schizophrenia, 531
  molecular mechanisms in schizophrenia, 173
  neuropsychologic deficits in relatives of schizophrenic patients, 120
  no parent-of-origin effect in schizophrenia, 706
  in obsessive–compulsive disorder, 1210
  PET imaging of transgene expression, 337
  in responses to antidepressants, 875-ed
  serotonin transporter gene polymorphisms in disorders, 259, 319
  sex chromosome abnormality in transsexualism, 1116

Genomics
  data analysis issues in microarray technology, 1147
  and neurobiology of anxiety and fear, 1144

Glial cells
  decreased numbers in bipolar disorder, 486
  loss in prefrontal cortex in depression, 766
  Glial fibrillary acidic protein
    immunoreactivity in depression affected by age, 861

Glucocorticoids. See Adrenal steroids

Glucose metabolism, cerebral
  in anxiety with affective disorders, 1020
  regional effects of fluoxetine in depression, 830

Glutamate
  and dopamine responses to amphetamine, 627
  interactions with serotonin in obsessive–compulsive disorder, 1210
  and neurotoxicity in hippocampus, 755

Glycogen synthase kinase 3β
  and therapeutic effects of mood stabilizers, 740

Go/No Go task
  and response inhibition in schizophrenia or psychopathy, 210

gp120
  neurotoxicity in HIV infection affected by glucocorticoids, 881

Granulocyte colony-stimulating factor
  plasma levels in clozapine-induced neutropenia, 1113

Gray matter volume
  lithium affecting, 740

Growth hormone
  serum levels in depressed children, 981

GRP78 and GRP94
  expression affected by valproate, 658

Guilt-related imagery
  PET studies of, 43

Haloperidol
  as antimanic agent, 539

Heart rate
  gambling affecting, 948

Herpes simplex virus
  thymidine kinase reporter gene expression, 337

Hippocampus
  abnormalities affecting cognition in schizophrenia, 1121
  imidazoline receptor proteins in depression, 910
  metabolic effects of fluoxetine in depression, 830
  MRI of men with bipolar disorder or schizophrenia, 147
  muscarinic receptors in schizophrenia, 381
  neurogenesis in adults, 715
  neuron death in depression, 755
  structural plasticity, 721
    in mood disorders, 732
    valproate affecting endoplasmic reticulum stress proteins, 658
    volume loss in depression, 791
      in aged subjects, 301

Histamine
  H<sub>2</sub> antagonist preventing weight gain in schizophrenia, 166

HIV infection
  and neurotoxicity affected by steroid hormones, 881

Hypochondriasis
  family studies of, 287

Hypothalamic–pituitary–adrenal axis
  cold pressor test in Alzheimer’s disease, 247
  and depression affecting salivary cortisol levels, 70
  desensitization of, and vasopressin in depression, 330
  function in depression, 791, 801
  stress affecting, 721
Metabolism, cerebral
   and anxiety in mood disorders, 1020
   regional effects of fluoxetine in depression, 830
N-Methyl-D-aspartate (NMDA)
   and dopamine responses to amphetamine, 627
   receptor activation
      affecting neurogenesis in adults, 715, 721
      and glutamatergic neurotoxicity, 755
Microdialysis samples
   dopamine release in prefrontal cortex affected by
      ziprasidone, 229
Mirtazapine
   in bipolar depression, 558
   and sleep continuity in depression, 75
Mitogen-activated protein kinase
   and cell survival in mood disorders, 732
   and expression of bcl-2 protein, 740
Moclobemide
   in bipolar depression, 558
Molecular biology
   mechanisms in schizophrenia, 173
Monoamine oxidase inhibitors
   in bipolar depression, 558
Mood disorders. See Bipolar disorder; Depression
Mood stabilizers
   mecamylamine affecting bipolar disorder in Tourette’s
      syndrome, 1028
   neurotrophic effects of, 740, 766
Muscarinic receptors
   in schizophrenia, 381
N200 amplitude
   in Stop signal task, 238
N275 amplitude
   in Go/No Go trials, 210
Naloxone
   ACTH responses to, 310
National Depressive and Manic-Depressive Association
   commentary on bipolar disorder, 442
National Institute of Mental Health
   research goals for bipolar disorder, 436
Nefazodone
   in bipolar depression, 558
Negative symptoms
   in schizotaxia, 349
Neural pathways
   in sadness and anxiety, 30
   in schizophrenia, 81
Neurodevelopment
   amygdala volumes in pediatric anxiety, 51
   in schizophrenia
      and bcl-2 protein expression, 641
      frontal lobe abnormalities in, 110
      molecular mechanisms in, 173
Neurogenesis, hippocampal
   in adults, 715, 721
   and cell survival in mood disorders, 732
   stress affecting, 801
Neuroleptics
   in bipolar depression, 558
Neuropeptides
   brain levels in bipolar disorder, 486
Neuroprotection
   and lithium activity, 1
Neuropsychologic function
   age affecting, in schizophrenia, 137
   and eyeblink conditioning in schizophrenia, 204
   findings in relatives of schizophrenic patients, 120
   in mood disorders, 674
Neurotoxicity
   in HIV infection, steroid hormones affecting, 881
Neuropathology
   and effects of mood stabilizers, 740
   and prefrontal cortex changes in mood disorders, 766
Neurotoxins
   brain levels in bipolar disorder, 486
Neutropenia
   clozapine-induced, granulocyte colony-stimulating factor
      levels in, 1113
Nicotinic receptor antagonist
   affecting bipolar disorder in Tourette’s syndrome, 1028
Nightmares
   in posttraumatic stress disorder, 1081
Nizatidine
   preventing olanzapine-related weight gain in schizophrenia,
      166
Norepinephrine
   brain levels in bipolar disorder, 486
   response to cold pressor test in Alzheimer’s disease, 247
   transporter binding by paroxetine, 954-corr
Nortriptyline
   in bipolar depression, 558
Object recognition
   episodic, in schizophrenia, 651
Object retrieval
   deficits from phencyclidine in monkeys, 415
Obsessive–compulsive disorder
   and CSF oxytocin and vasopressin levels in eating
      disorders, 315
   genetics and neuroimaging in, 1210
   pediatric, thalamic volume in, 294
   relation to other spectrum conditions, 287
Olanzapine
   as antimanic agent, 539
   in bipolar depression, 558
   as maintenance therapy in bipolar disorder, 573
   in schizophrenia, and weight gain prevention by nizatidine,
      166
Opioid receptor blockade
   ACTH responses to, 310
Opponent processes
   and arousal in schizophrenia, 81
Oppositional defiant disorder
   familial association with attention-deficit disorder, 21
Orbitofrontal cortex
  abnormalities in schizophrenia, 110
  cytosolic choline levels in adolescent depression, 1053
  volume reduction in geriatric depression, 971
Outcome assessment
  birth outcomes after fluoxetine in pregnancy, 996
  effects of substance abuse in bipolar disorder, 477
  6-month outcome measures in first episodes, 467
Oxcarbazepine
  as antimanic agent, 539
Oxygen radicals
  and hippocampal neuron loss, 755
Oxytocin
  CSF levels after recovery from eating disorders, 315
  P3a amplitude
    in male alcoholics, 276
  P300 amplitude
    lateralized deficit in schizotypal personality disorder, 702
    and onset of adolescent alcohol use, 265
  P375 amplitude
    in Go/No Go trials, 210
Panic disorder
  and carbon dioxide challenge test in relatives of patients,
    1223-corr
Paralimbic structures
  in guilt-related imagery, 43
Paroxetine
  binding to norepinephrine transporter, 954-corr
Personality disorder
  schizotypal, lateralized P3 deficit in, 702
PET studies
  cingulate and caudate activity in mania, 1045
  in depression, 813
  episodic object recognition in schizophrenia, 651
  in guilt-related imagery, 43
  metabolism in anxiety with mood disorders, 1020
  neuroimaging in bipolar disorder, 505
  pindolol augmentation of antidepressants, 844
  regional cerebral blood flow affected by high and low
    frequencies in transcranial magnetic stimulation, 1133
  regional metabolic effects of fluoxetine in depression, 830
  sadness and anxiety, 30
  serotonin receptors
    binding affected by estradiol and progesterone, 854
    in depression, 801
    transgene expression, 337
Pharmacogenetics
  in obsessive–compulsive disorder, 1210
Pharmacology
  and molecular mechanisms in schizophrenia, 173
Phencyclidine
  and object retrieval deficits in monkeys, 415
Phenelzine
  in bipolar depression, 558
Phospholipid turnover in basal ganglia affected by cocaine, 685
Phototherapy
  in bipolar depression, 558
  Phototransduction, extracellular
    and skin light exposure affecting melatonin and bilirubin
    levels, 1098
Physical illness
  in depressed patients, 791
Pindolol
  augmentation of antidepressant treatment, 844
  in bipolar depression, 558
  serotonin receptor occupancy at presynaptic and
    postsynaptic sites, 801
Pineal gland
  melatonin levels affected by skin light exposure, 1098
  [3 H]Pirenzepine
    binding muscarinic receptors in schizophrenia, 381
Polysomnography
  in depression, mirtazapine affecting, 75
Postmortem studies
  age affecting glial fibrillary acidic protein immunoreactivity
    in depression, 861
  altered numbers of cells in mood disorders, 766
Posttraumatic stress disorder
  comorbidity with depression, 878-ed, 902
  and initial urinary cortisol levels after trauma, 940
  trauma-related nightmares in, 1081
Postural sway
  and onset of adolescent alcohol use, 265
Potassium
  Na,K-ATPase activity in bipolar disorder, 486
Prefrontal cortex
  activation in schizophrenia, 99
  age affecting glial fibrillary acidic protein immunoreactivity
    in depression, 861
  anatomy in obsessive–compulsive disorder, 1210
  cell loss in mood disorders, 766
  dopamine release affected by ziprasidone, 229
  dysfunction from phencyclidine in monkeys, 415
  and episodic object recognition in schizophrenia, 651
  metabolic effects of fluoxetine in depression, 830
  neuroimaging in depression, 813
  responses in schizophrenia, 81
  synaptophysin mRNA levels in schizophrenia, 389
  transcranial magnetic stimulation in depression, 962
Pregnancy
  and antidepressant concentrations in amniotic fluid, 1032
  fluoxetine in, affecting birth outcomes, 996
Premenstrual dysphoric disorder
  cortisol circadian rhythms in, 920
Problem solving
  in mood disorders, 674
Progesterone
  affecting serotonin receptor binding, 854
Protein kinase C
  activity in bipolar disorder, 486
  and signal transduction, 518
Psychoeducational program
  in bipolar disorder, 582
Psychopathy
response inhibition in, 210

Psychotherapy
in bipolar depression, 558
interpersonal and social rhythm therapy in bipolar disorder, 593

Pulvinar region
and episodic object recognition in schizophrenia, 651

Pupillometry
time-of-day variations in, 1069

Quetiapine
as antimanic agent, 539
in bipolar depression, 558

Reboxetine
in bipolar depression, 558

Recurrence of episodes
in bipolar disorder, 445

Reporter genes
PET imaging of transgene expression, 337

Research
flexible treatment in chronic disease, 605
goals for bipolar disorder, 436

Response inhibition
in attention-deficit/hyperactivity disorder, 238
in schizophrenia or psychopathy, 210

Risperidone
as antimanic agent, 539
in bipolar depression, 558
as maintenance therapy in bipolar disorder, 573
in schizotaxia, 349

mRNA
aldolase A levels affected by lithium, 58
corticotropin-releasing hormone levels
in animal models of anxiety, 1175
and stress reactivity affected by maternal care, 1164
and synaptic protein genes in schizophrenia, 184

Rubber hand illusion
in schizophrenia, 1105

Saccades
in attentional dysfunction, 197

Sadness
neural correlates of, 30

Saliva
cortisol levels
in children, related to mother’s depression, 976
depression affecting, in twins, 70
gambling affecting, 948
dehydroepiandrosterone levels in major depression, 989

Schizophrenia
fine structure of auditory M100 in, 1109

Schizoaffective disorder
fine structure of auditory M100 in, 1109

Schizotypal personality disorder
features and treatment protocols, 349

Serotonin
brain levels in bipolar disorder, 486
complex (dys)function of transporter, 334-corr
depression relapse in tryptophan depletion, 327
5-HT1A receptor
activation by ziprasidone, 229
knockout mice expressing fear and anxiety, 1157
5-HT2A receptor binding affected by estradiol and progesterone, 854
neurotransmission in depression, 801
reuptake inhibitors
augmentation by pindolol, 84
in bipolar depression, 558
citalopram and sertraline compared, 894
comparisons of, 875-ed, 894
transporter gene polymorphism in disorders, 259, 319

Sertraline
compared to citalopram, 894

Sex chromosomes
abnormality in transsexualism, 1116

Signal transduction
in bipolar disorder, 518
calcium homeostasis affecting, 665

associative learning in, 406
and cerebellar function, 204
basal ganglia activation in, 99
bcl-2 protein expression in, 641
brain morphometrics in first episode, 398
cerebellar function in, 204
cognitive function in
and reactivity to stress, 1119
and symptom severity related to cortisol levels, 1121
ECT efficacy affected by stimulus intensity, 222
emotion recognition in, 127
episodic object recognition in, 651
fine structure of auditory M100 in, 1109
magnetic resonance spectroscopy in, 357, 369
molecular mechanisms in, 173
MRI of temporal lobe structures in men, 147
muscarinic receptors in, 381
neuropsychologic deficits in relatives of schizophrenic patients, 120
olanzapine-related weight gain prevention with nizatidine, 166
parent-of-origin effect in, 706
prevention goals, 349
relation to bipolar disorder, 531
response inhibition in, 210
resting EEG abnormalities in, 1088
smooth pursuit eye movements in, 197
synaptic proteins in, 184
synaptophysin mRNA levels in, 389
touch feel illusion in, 1105

Schizotaxia
features and treatment protocols, 349

Serotonin complex (dys)function of transporter, 334-corr
depression relapse in tryptophan depletion, 327
5-HT1A receptor
activation by ziprasidone, 229
knockout mice expressing fear and anxiety, 1157
5-HT2A receptor binding affected by estradiol and progesterone, 854
neurotransmission in depression, 801
reuptake inhibitors
augmentation by pindolol, 84
in bipolar depression, 558
citalopram and sertraline compared, 894
comparisons of, 875-ed, 894
transporter gene polymorphism in disorders, 259, 319

Sertraline compared to citalopram, 894

Sex chromosomes abnormality in transsexualism, 1116

Signal transduction in bipolar disorder, 518
calcium homeostasis affecting, 665
Skin
  light exposure affecting melatonin and bilirubin levels, 1098

Sleep
  architecture and obstructive apnea in depression, 1001
  diurnal fluctuation in menstrual cycle, 1062
  mirtazapine affecting, in depression, 75
  reliability of computer analysis of EEG in, 1010
  and trauma-related nightmares, 1081

Sleep deprivation
  cortisol circadian rhythms in, 920
  as therapy in bipolar depression, 558
  thyroid function in, 323

Sleepiness
  time-of-day variations in, 1069

Social rhythm therapy
  in bipolar disorder, 593

Socioeconomic status
  and cortisol levels in children related to mother’s depression, 976

Sodium
  Na,K-ATPase activity in bipolar disorder, 486

SPECT studies
  ketamine affecting amphetamine-induced dopamine release, 627
  neuroimaging in bipolar disorder, 505
  serotonin transporter in depression, 801

Splenium
  morphology in schizophrenia, 398

Stop signal task
  and response inhibition in attention-deficit disorder, 238

Stress. See also Posttraumatic stress disorder
  and adaptive plasticity in hippocampus, 721
  and altered fear circuits in knockout mice, 1157
  and brain changes in depression, 791
  corticotropin-releasing hormone in, 1175
  early events affecting brain structure and function, 778
  and neurogenesis in adults, 715
  neuronal activity and cell survival in, 732
  prefrontal cortex cell loss in, 766
  reactivity
    affected by cognition in schizophrenia, 1119
    affected by maternal care in infancy, 1164
    serotonin receptors in, 801

Striatum
  anatomy in obsessive–compulsive disorder, 1210
  metabolic effects of fluoxetine in depression, 830
  neuroimaging in depression, 813

Substance abuse. See Alcoholism; Drug abuse

Suicidal behavior
  hippocampal imidazoline receptor proteins in, 910
  serotonin transporter gene polymorphisms in, 259, 319

Sympathetic nervous system
  response to cold pressor test in Alzheimer’s disease, 247

Synaptic proteins
  brain levels in bipolar disorder, 486
  in schizophrenia, 184

Synaptophysin
  mRNA levels in schizophrenia, 389

T cells
  natural killer cells in aged depressed patients, 1024
  and anxiety symptoms, 1199

Temperature
  core body rhythm in menstrual cycle, 1062
  as therapy in bipolar disorder, 558

Thalamus
  anatomy in obsessive–compulsive disorder, 1210
  and episodic object recognition in schizophrenia, 651
  neuroimaging in depression, 813
  synaptophysin mRNA levels in schizophrenia, 389
  volume in pediatric obsessive–compulsive disorder, 294

Therapeutic response
  and plasma thymopoietin in depression, 65

Thymopoietin
  plasma levels in depression, 65

Thyroid gland
  function in sleep deprivation, 323
  hormone therapy
    in bipolar depression, 558
    as maintenance therapy in bipolar disorder, 573
  stimulating hormone
    diurnal fluctuation in menstrual cycle, 1062

Tiagabine
  as antimanic agent, 539

Topiramate
  as antimanic agent, 539

Touch feel illusion
  in schizophrenia, 1105

Tourette’s syndrome
  and response to mecamylamine in bipolar disorder, 1028

Transsexualism
  sex chromosome abnormality in, 1116

Tranilcypromine
  in bipolar depression, 558

Trauma
  initial urinary cortisol levels predicting posttraumatic stress disorder, 940
  and pediatric mania, 458

Tricyclic antidepressants
  in bipolar depression, 558

Tryptophan depletion
  and risk of depression relapse, 327

Twins
  depression affecting salivary cortisol levels, 70
  temperament related to anxiety, 1199

Umbilical cord blood
  antidepressant concentrations in, 1032

Unmedicated psychosis
  and effects of subsequent treatment, 163
Valproate
  as antimanic agent, 539
  and expression of endoplasmic reticulum stress proteins, 658
  neurotrophic and neuroprotective effects, 740
Vasopressin
  CSF levels after recovery from eating disorders, 315
  plasma levels in depression, 330
Venlafaxine
  in bipolar depression, 558
Visual event-related potentials
  and onset of adolescent alcohol use, 265
  and response inhibition
    in attention-deficit disorder, 238
    in schizophrenia or psychopathy, 210
[¹¹C]WAY-100635
  in PET studies of pindolol augmentation of antidepressants, 844
Weight gain
  olanzapine-associated, prevention by nizatidine, 166
Working memory
  in mood disorders, 674
  in schizophrenia, 99
Ziprasidone
  as antimanic agent, 539
  and dopamine release in prefrontal cortex, 229
Zonisamide
  as antimanic agent, 539